Table 1. Baseline characteristics.

Characteristic	All patients (n=301)	PET/CT (n=92)	No PET/CT (n=209)
Median age (range) (years)	59 (31–85)	57 (35–77)	60 (31–85)
Female	67 (22.3%)	22 (23.9%)	45 (21.5%)
Male	234 (77.7%)	70 (76.1%)	164 (78.5%)
Tumour site
Oral cavity	4 (1.3%)	0	4 (1.9%)
Oropharynx	194 (64.5%)	68 (74.0%)	126 (60.3%)
Larynx	75 (24.9%)	12 (13.0%)	63 (30.1%)
Hypopharynx	28 (9.3%)	12 (13.0%)	16 (7.7%)
T stage
Tx	2 (0.7%)	0	2 (1.0%)
T1	30 (10.0%)	7 (7.6%)	23 (11.0%)
T2	90 (29.9%)	24 (26.1%)	66 (31.6%)
T3	94 (31.2%)	25 (27.2%)	69 (33.0%)
T4	85 (28.2%)	36 (39.1%)	49 (23.4%)
N stage
N0	101 (33.6%)	15 (16.3%)	86 (41.1%)
N1	46 (15.3%)	14 (15.2%)	32 (15.3%)
N2A	22 (7.3%)	11 (12.0%)	11 (5.3%)
N2B	82 (27.2%)	30 (32.6%)	52 (24.9%)
N2C	34 (11.3%)	18 (19.6%)	16 (7.7%)
N3	16 (5.3%)	4 (4.3%)	12 (5.7%)
Neoadjuvant chemotherapy
Yes	53 (17.6%)	39 (42.4%)	14 (6.7%)
No	248 (82.4%)	53 (57.6%)	195 (93.3%)
Concurrent chemotherapy
Carboplatin (2 cycles)	209 (69.4%)	65 (70.7%)	144 (68.9%)
Carboplatin (1 cycle)	56 (18.6%)	15 (16.3%)	41 (19.6%)
Cetuximab	36 (11.9%)	12 (13.0%)	24 (11.5%)

PET, positron emission tomography.